Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 08 May 2018 Status changed from not yet recruiting to recruiting.
- 25 Jan 2018 New trial record